Lupin receives final approval for Fluocinonide Topical Ointment

From USFDA

Lupin has received final approval for its Fluocinonide Topical Ointment USP, 0.05% from the United States Food and Drug Administration to market a generic version of County Line Pharmaceuticals, LLC's Lidex Ointment, 0.05%. It is indicated for the relief of the inflammatory and pruritic manifestation of corticosteroid-responsive dermatoses.

Powered by Capital Market - Live News